The special dividend is a deal-contingent event — monitor stockholder votes and regulatory approvals for the merger. If the merger closes, the dividend provides a near-term cash return; if it fails, the dividend is canceled. No standalone operational catalyst.
Price Chart
Executive Summary
Indivior declared a special cash dividend of $8.13 per share, contingent on the closing of its previously announced merger with Supernus Pharmaceuticals. The merger is expected to close around November 2, 2026, subject to stockholder approvals and other conditions. This dividend is a deal-contingent capital return event, not a standalone financial signal.
Key Facts
- Special dividend of $8.13 per share declared, contingent on merger closing.
- Merger with Supernus Pharmaceuticals expected to close on or about November 2, 2026.
- Dividend payable to holders of record as of October 30, 2026, and to holders of certain equity awards.
- Dividend will not be paid if merger does not close.
- Supernus stockholders will not receive the special dividend on shares received as merger consideration.
Financial Impact
Special dividend of $8.13 per share; total payout depends on shares outstanding at record date. Merger value not restated in this press release.
Risk Factors
- Merger may not close due to failure to obtain stockholder or regulatory approvals.
- Dividend is contingent on merger closing — no payment if deal fails.
- Market price of INDV may fluctuate on merger-related news and timeline uncertainty.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3363844 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Institutional Cluster | $34.79 | awaiting T+60 | — | $34.47 (−0.92%) |
Oct 19, 2026 7d ago | Press Release | $33.87 | awaiting T+60 | — | $34.47 (+1.77%) |
Oct 6, 2026 20d ago | 425 | $35.90 | awaiting T+60 | — | $34.47 (−3.98%) |
Oct 6, 2026 20d ago | 8-K | $35.90 | awaiting T+60 | — | $34.47 (−3.98%) |
Sep 30, 2026 26d ago | SC 13G | $35.38 | awaiting T+60 | — | $34.47 (−2.57%) |
Sep 17, 2026 5w ago | 425 | $35.69 | awaiting T+60 | — | $34.47 (−3.42%) |
Sep 17, 2026 5w ago | 8-K | $35.69 | awaiting T+60 | — | $34.47 (−3.42%) |
Sep 17, 2026 5w ago | Press Release | $35.69 | awaiting T+60 | — | $34.47 (−3.42%) |
Sep 14, 2026 6w ago | EFFECT | $34.47 | awaiting T+60 | — | $34.47 (+0.00%) |
Aug 28, 2026 8w ago | S-4 | $34.93 | awaiting T+60 | — | $34.47 (−1.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers